Project Grant HT9425261E212
Award Date 7/1/26
Completion Date 6/30/29
Dollars Obligated $1.2M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
- Federal Project Grant Award Summary The University of Texas MD Anderson Cancer Center received a $5.47M Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective September 1, 2025, through August 31, 2029. The award funds research aimed at targeting ganglioside GD2 to overcome chemotherapy resistance in triple-negative breast cancer. This research initiative represents translational and clinical investigation...
- Federal Grant Award Summary The University of Texas MD Anderson Cancer Center received a $349,976 project grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) for the period July 1, 2026, through June 30, 2028. The award funds research focused on intercepting omental metastasis of ovarian cancer by targeting a mitochondrial redox-interleukin-10 (IL-10) axis in the immune microenvironment. This translational research initiative...
- Federal Project Grant Award Summary The University of Texas MD Anderson Cancer Center received a $1,099,986 project grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), awarded on June 1, 2026, with a completion date of May 31, 2030. The award funds research focused on metabolic rewiring of chimeric antigen receptor T (CAR-T) cells to overcome the hostile tumor microenvironment in pancreatic cancer. This four-year research...
- Federal Grant Award Summary The University of Texas MD Anderson Cancer Center received a $347,581 project grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) for the period of June 1, 2026, through May 31, 2028. The award supports research investigating ovarian cancer dormancy induced by metabolic alterations, a translational research initiative aligned with the DHA's mission to advance innovative biomedical solutions for...
- Federal Project Grant Award Summary The University of Texas MD Anderson Cancer Center received a $932,350 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective August 15, 2025, through August 14, 2028. The grant supports the development and evaluation of an in situ tumor vaccine designed to stimulate antitumor immunity against breast cancer. This three-year research initiative will be conducted at MD...
- Federal Grant Award Summary The University of Texas MD Anderson Cancer Center received a $489,767 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) effective October 1, 2025, through September 30, 2028. The award supports research titled "Building T-Cell Products in NF1-Associated MPNST Through Antigen Discovery and Epigenome Targeting," which addresses the development of therapeutic T-cell immunotherapy...
- Federal Grant Award Summary The University of Texas MD Anderson Cancer Center received a $1.35 million Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) for the three-year period from October 1, 2025, through September 30, 2028. The award funds research focused on building T-cell products for neurofibromatosis type 1 (NF1)-associated malignant peripheral nerve sheath tumors (MPNST) through antigen discovery and...
- Federal Grant Award Summary The University of Texas MD Anderson Cancer Center received a $349,996 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) for the period June 15, 2026 through June 14, 2028. The award funds research on metabolic rewiring of chimeric antigen receptor (CAR)-T cells to counter the hostile tumor microenvironment in ovarian cancer. This research aims to develop enhanced immunotherapy approaches by...
- Federal Project Grant Award Summary The University of Texas MD Anderson Cancer Center received a $1,431,215 project grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) awarded October 1, 2025, with a completion date of September 30, 2028. The award funds research focused on building T-cell products for neurofibromatosis type 1 (NF1)-associated malignant peripheral nerve sheath tumors (MPNST) through antigen discovery and...
- Federal Project Grant Award Summary The University of Texas MD Anderson Cancer Center received a $817,496 project grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) effective September 1, 2025, through August 31, 2028. The award funds research to investigate the PRMT3-IGF2BP1 axis-mediated epitranscriptomic reprogramming as a novel therapeutic strategy to overcome immunotherapy resistance in clear cell renal cell carcinoma...